- Femasys Inc.
Femasys Inc.
Website
We are a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. Our mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. As a woman-founded and led company with an expansive, internally created intellectual property portfolio with over 100 patents globally, in-house CMC and device manufacturing capabilities and proven ability to develop and commercialize products, we believe that we are well-positioned to become a leading company in the women’s healthcare space with solutions to address multi-billion dollar global opportunities.
Our suite of products and product candidates address several large global market segments in which there has been little advancement for many years, helping women avoid pharmaceutical solutions, implants and surgery that can be expensive and expose women to harm. With an initial focus in the area of reproductive health, our two lead product candidates offer solutions for two ends of the spectrum: FemBloc for permanent birth control and FemaSeed as an artificial insemination infertility treatment. We believe our solutions have the potential to disrupt and grow the market segments that they address with few or no current direct competitors.
Offering Team
Deal Managers
- Chardan Capital
- JonesTrading
Lawyers
- Dechert LLP
Auditors
- KPMG LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
Deal Tracker
Investors
Filing
17 Jun, 2021Offer
18 Jun, 2021Look Ahead
Lock Up Expiry
18 Dec, 2021Earning
Nov 1, 2018IPO Terms
| Offer Price | $13.00 |
| Offer Size | 2M |
